zu ASX:CYP - Cynata
neuer Forumsteilnehmer mit Expertise in Diskussion mit Pfeiffer, für Interessierte.
https://hotcopper.com.au/threads/fomo-is-coming.4630427/page…
zabba 198:
I am a neuroscientist focussing on developing pluripotent stem cells to model neurodegenerative disorders, in-vitro. I may be biased, however, $CYP is incredibly appealing to me for the following brief reasons ....
Why? induced pluripotent stem cell derived mesenchymal stem cells (MSCs) for the treatment of limb ischemia and GvHD removes a lot of heterogeneity associated with third-party treatments and rather focussing on deriving stem cells from the patients own fibroblasts. The time to do so may be lengthy, but the results evidently speak for themselves. They can create large amounts of mesenchymal stem cells from small samples. Clearly they are already doing this ... "Conversely, since iPSCs can proliferate indefinitely, and MCAs themselves can expand into extremely large quantities of MSCs, Cynata expects to be able to manufacture all of the cells that it will ever need from a single Master Cell Bank of iPSCs – derived from a single donor."
Majority of biotech / pharma companies have issues with their products due to disease heterogeneity. However, $CYP reduces this by developing MSCs from patients using pluripotent stem cell technology.
In the future, $CYP may explore deriving these for individual patients rather than one donor - unless this has been updated, I can't find a lot on it in their announcements. This would create larger banks, and further reduce variability.
Once establishing mesenchymal stem cells, MCAs can be used to make a range of cell types. Hence, the thought of positive results for lower limb ischemia seems very plausible from an initial outset.
ALL IMO ETC.
What a great company. Will look to purchase V soon.
Share
+++ der Kurs ist übrigens deutlich angesprungen, es läuft die deadline für Fuji sich zu CYP im März zu erklären, Fuji startet eine großes Firmengebäude in den USA zur Produktion (milestone, Start phase 2)
